When was CellCentric founded?

CellCentric was founded in 2003 and raised its 1st funding round within a year of its incorporation.

Where is CellCentric located?

CellCentric is headquartered in Cambridge, United Kingdom. It is registered at Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL.

Who is the current CEO of CellCentric?

Will West of CellCentric. They have also founded 1 company.

Which legal entities is CellCentric associated with?

CellCentric is associated with Cellcentric Limited.

How many employees does CellCentric have?

As of Jun 30, 2026, the latest employee count at CellCentric is 58.

Is CellCentric a funded company?

CellCentric is a funded company, having raised a total of $430M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 03, 2003.

When was the latest funding round of CellCentric?

CellCentric's latest funding was a $***** Series D round on May 06, 2026, with participation from 1 investor.

Where does CellCentric rank among its competitors?

CellCentric ranks 221st amongst 3261 active competitors, of which 1122 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of CellCentric?

CellCentric's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

CellCentric - 2026 Company Profile, Team, Funding, Competitors & Financials

CellCentric is a series D company based in Cambridge (United Kingdom), founded in 2003 by Will West and Azim Surani. It operates as a Developer of oral small molecule inhibitors for treating blood cancers. CellCentric has raised $430M in funding from investors like RA Capital Management, Venrock and Morningside. The company has 3261 active competitors, including 1122 funded and 772 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Developer of oral small molecule inhibitors for treating blood cancers. This pharmaceutical entity focuses on creating therapeutic agents that target specific proteins involved in tumor progression. The research involves modulating gene expression by disrupting the interaction of transcription co-activation factors within cancer cells. The primary therapeutic candidate is designed to address multiple myeloma and other hematological malignancies by binding to bromodomains. This approach aims to reduce the production of proteins that drive tumor growth. The development process includes clinical evaluation to assess safety and efficacy across various patient populations.

Website: www.cellcentric.com/
Social
Email ID: *****@cellcentric.com
Phone Number: +44 **********
Registered Address: Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL

Key Metrics

Founded Year

2003

Location

Cambridge, United Kingdom

Stage

Series D

Total Funding

$430M in 13 rounds

Latest Funding Round

Series D, May 06, 2026, $*****

Investors

RA Capital Management & 51 more

Ranked

221^st among 3261 active competitors

Employee Count

58 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2977 more

View CellCentric's full profile

CellCentric is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cellcentric Limited CIN: 4948632 , Germany, Active	Oct 29, 2003	-	19 (As on Dec 31, 2024)

CellCentric has raised a total funding of $430M over 13 rounds. Its first funding round was on Jun 03, 2003. Its latest funding round was a Series D round on May 06, 2026 for $*****. 1 investor participated in its latest round. CellCentric has 26 institutional investors and 26 angel investors.

Here is the list of recent funding rounds of CellCentric:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 06, 2026	1753502	Series D	7811818	6750311	3391193	3984586
May 19, 2025	7448867	Series C	7530029	9532331	4326056	Avego & 1 more
Jul 24, 2024	4060860	Series C	3785790	6288780	RA Capital Management	7618821

Access funding benchmarks and valuations. Sign up today!

View details of CellCentric's funding rounds and investors

The founders of CellCentric are Will West and Azim Surani. Will West is the CEO of CellCentric.

Here are the details of CellCentric's key team members:

Will West: Co-Founder & CEO of CellCentric. They serve on the board of 1 company.
Azim Surani: Co-Founder of CellCentric.
Contact Info: 1 email address

CellCentric's Board of Directors

CellCentric's board has 6 active members. Will West and Andrew Hughes are part of team and Laura Smith, Irena Melnikova, Jason Robert Dinges and Jasper Bos are independent board members.

Here is the list of CellCentric's board of directors:

Name	Type	Representing	Status	Duration
Will West	Team	-	Current	21y 3m
Andrew Hughes	Investor	-	Current	4y 2m
Laura Smith	Independent board member	-	Current	1y 11m
sgsuctd	Independent board member	-	Current	4y 3m
xawleqq	Independent board member	-	Current	5y 9m
tk{hopt	Independent board member	-	Current	6y 1m
mdehlqu	Independent board member	-	Past	7y 1m
bnzmkip	Independent board member	-	Past	7y 7m
qbdtgef	Independent board member	-	Past	5y 7m
tgbtpqc	Independent board member	-	Past	6y 7m
kwygltl	Independent board member	-	Past	3y 4m
ycmdgon	Independent board member	-	Past	4y 3m
ye{vrfk	Independent board member	-	Past	4y 6m
ygpvury	Independent board member	-	Past	6y 1m
s{rbrjg	Independent board member	-	Past	9y 6m
skzdgts	Independent board member	-	Past	3y 1m
tjiminp	Independent board member	-	Past	3y 1m
jqlev{y	Independent board member	-	Past	2y 6m

View details of CellCentric's Founder profiles and Board Members

CellCentric's employee count trend

CellCentric has 58 employees as of Jun 26. Here is CellCentric's employee count trend over the years:

Uncover CellCentric's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CellCentric include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of CellCentric, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
221st	CellCentric 2003, Cambridge (United Kingdom), Series D	Developer of oral small molecule inhibitors for treating blood cancers	$430M	Venrock, Pfizer & 50 others	59/100